(VIANEWS) – Erie Indemnity Company (ERIE), American National Bankshares (AMNB), Regeneron Pharmaceuticals (REGN) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Erie Indemnity Company (ERIE)
11% sales growth and 26.99% return on equity
Erie Indemnity Company operates as a managing attorney-in-fact for the subscribers at the Erie Insurance Exchange in the United States. The company provides sales, underwriting, policy issuance, and renewal services for the policyholders on behalf of the Erie Insurance Exchange. It also offers sales related services, including agent compensation, and sales and advertising support services; and underwriting services comprise underwriting and policy processing; and other services consist of customer services and administrative support services, as well as information technology services. Erie Indemnity Company was incorporated in 1925 and is based in Erie, Pennsylvania.
Earnings Per Share
As for profitability, Erie Indemnity Company has a trailing twelve months EPS of $7.66.
PE Ratio
Erie Indemnity Company has a trailing twelve months price to earnings ratio of 44.73. Meaning, the purchaser of the share is investing $44.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.99%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 15.9%, now sitting on 3.15B for the twelve trailing months.
Sales Growth
Erie Indemnity Company’s sales growth is 10.3% for the present quarter and 11% for the next.
Volume
Today’s last reported volume for Erie Indemnity Company is 131299 which is 31.72% above its average volume of 99677.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Jan 4, 2024, the estimated forward annual dividend rate is 5.1 and the estimated forward annual dividend yield is 1.49%.
2. American National Bankshares (AMNB)
9% sales growth and 7.87% return on equity
American National Bankshares Inc. operates as the bank holding company for American National Bank and Trust Company that provides financial products and services in Virginia and North Carolina. The company operates through two segments, Community Banking, and Trust and Investment Services. It accepts deposit products, including checking, money market, savings, and consumer and commercial time deposits, as well as certificates of deposit. The company's loan products comprise commercial and residential real estate loans, commercial loans to small and medium-sized businesses, construction and land development loans, home equity loans, mortgage loans, and consumer loans. It also offers trust and investment services, such as estate planning, trust account administration, and retail brokerage services; online and telephone banking services; insurance services; and investment management services, including purchasing equity, fixed income, and mutual fund investments for customer accounts, as well as operates 37 automated teller machines. As of December 31, 2020, it operated 26 banking offices; and one loan production offices in Roanoke, Virginia. American National Bankshares Inc. was founded in 1909 and is headquartered in Danville, Virginia.
Earnings Per Share
As for profitability, American National Bankshares has a trailing twelve months EPS of $2.46.
PE Ratio
American National Bankshares has a trailing twelve months price to earnings ratio of 19.34. Meaning, the purchaser of the share is investing $19.34 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.87%.
Sales Growth
American National Bankshares’s sales growth is negative 0.7% for the present quarter and 9% for the next.
Yearly Top and Bottom Value
American National Bankshares’s stock is valued at $47.57 at 19:22 EST, under its 52-week high of $50.76 and way higher than its 52-week low of $25.26.
3. Regeneron Pharmaceuticals (REGN)
8.3% sales growth and 17.22% return on equity
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Earnings Per Share
As for profitability, Regeneron Pharmaceuticals has a trailing twelve months EPS of $35.05.
PE Ratio
Regeneron Pharmaceuticals has a trailing twelve months price to earnings ratio of 27.05. Meaning, the purchaser of the share is investing $27.05 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.22%.
Previous days news about Regeneron Pharmaceuticals(REGN)
- According to Zacks on Wednesday, 31 January, "A couple of better-ranked stocks in the healthcare industry are Novo Nordisk (NVO Quick QuoteNVO – Free Report) and Regeneron Pharmaceuticals (REGN Quick QuoteREGN – Free Report) . "
4. Insperity (NSP)
5.6% sales growth and 264.61% return on equity
Insperity, Inc. engages in the provision of human resources (HR) and business solutions to improve business performance for small and medium-sized businesses. It offers its HR services through its Workforce Optimization and Workforce Synchronization solutions that include a range of human resources functions, such as payroll and employment administration, employee benefits, workers' compensation, government compliance, performance management, and training and development services. The company also provides Insperity Premier, a cloud-based human capital management platform that offers professional employer organization HR outsourcing solutions to its clients; people management services; and employer liability management services, as well as solutions for middle market. In addition, it offers MarketPlace, an e-commerce portal that offers a range of products and services; and Workforce Acceleration, a human capital management and payroll services solution; time and attendance; performance management; recruiting; employment screening; retirement; and insurance services. The company was formerly known as Administaff, Inc. and changed its name to Insperity, Inc. in March 2011. Insperity, Inc. was founded in 1986 and is headquartered in Kingwood, Texas.
Earnings Per Share
As for profitability, Insperity has a trailing twelve months EPS of $4.92.
PE Ratio
Insperity has a trailing twelve months price to earnings ratio of 23.35. Meaning, the purchaser of the share is investing $23.35 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 264.61%.
Sales Growth
Insperity’s sales growth is 6.3% for the ongoing quarter and 5.6% for the next.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Insperity’s EBITDA is 45.16.
Revenue Growth
Year-on-year quarterly revenue growth grew by 7.8%, now sitting on 6.4B for the twelve trailing months.
5. Charles Schwab (SCHW)
5.2% sales growth and 13.62% return on equity
The Charles Schwab Corporation, together with its subsidiaries, operates as a savings and loan holding company that provides wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. The company operates in two segments, Investor Services and Advisor Services. It offers brokerage accounts with equity and fixed income trading, margin lending, options trading, futures and forex trading, and cash management capabilities, including certificates of deposit; third-party mutual funds through the Mutual Fund Marketplace and Mutual Fund OneSource service, as well as mutual fund trading and clearing services to broker-dealers; exchange-traded funds; advisory solutions for managed portfolios, separately managed accounts, customized personal advice for tailored portfolios, specialized planning, and full-time portfolio management; banking products comprising checking and savings accounts, first lien residential real estate mortgage loans, home equity lines of credit, and pledged asset lines; and trust custody services, personal trust reporting services, and administrative trustee services. It also provides digital retirement calculators; integrated web-, mobile-, and software-based trading platforms, real-time market data, options trading, premium research, and multi-channel access; self-service education and support tools; online research and analysis tools; equity compensation plan sponsors full-service recordkeeping for stock plans, stock options, restricted stock, performance shares, and stock appreciation rights; and retirement plan services. The Company operates domestic branch offices in 48 states and the District of Columbia, as well as locations in Puerto Rico, the United Kingdom, Hong Kong, and Singapore. The Charles Schwab Corporation was founded in 1971 and is headquartered in Westlake, Texas.
Earnings Per Share
As for profitability, Charles Schwab has a trailing twelve months EPS of $2.54.
PE Ratio
Charles Schwab has a trailing twelve months price to earnings ratio of 24.78. Meaning, the purchaser of the share is investing $24.78 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.62%.
